3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
3
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
24
Neoplasm Metastasis
3
Neoplasms by Site
2
Neoplasms
2
Multiple Endocrine Neoplasia Type 1
2
Breast Diseases
2
Unilateral Breast Neoplasms
1
Recurrence
1
Osteitis Deformans
1
Locally Advanced (Inoperable) or Metastatic Breast Cancer
1
Hereditary Sensory and Autonomic Neuropathies
1
HR+/HER2- Breast Cancer
1
Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
1
Breast Neoplasms, Male
1
Anatomic Stage II Breast Cancer AJCC v8
1
Advanced Metastatic Breast Cancer
1
Advanced Breast Cancer
1
Interventions
Dexamethasone
28
Rituximab
16
pomalidomide
13
Gemcitabine
12
Lenalidomide
11
Cisplatin
11
Bortezomib
11
Paclitaxel
10
Cyclophosphamide
8
Carboplatin
8
carfilzomib
7
selinexor
5
daratumumab
5
Drug Therapy
5
Doxorubicin
5
Cytarabine
5
ibrutinib
4
Vincristine
4
Temozolomide
4
Prednisone
4
Docetaxel
4
Calcium Dobesilate
4
Bevacizumab
4
Aspirin
4
tisagenlecleucel
3
Cetuximab
3
Bendamustine Hydrochloride
3
venetoclax
2
ofatumumab
2
galiximab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Recurrence
×
ribociclib
×
Clear all
NCT06760637
2026-05-19
FourLight-3
Pfizer
Phase 3
Active not recruiting
1,035 enrolled